What the Recent Peptide Nomination Withdrawals Mean

Key Takeaways

• The FDA removed 12 peptides including BPC-157, TB-500, and MOTS-c from its Category 2 "do not compound" list in April 2026.
• This is not a green light to compound; the peptides remain in a regulatory gray zone.
• The FDA's advisory committee meets July 23–24, 2026 to review several peptides for 503A eligibility.
  
• Providers can submit public comments on regulations.gov through July 22.
  
• Designer Drugs Labs is already formulating and stability-testing to move quickly once a pathway opens.

Peptides like BPC-157, TB-500, and MOTS-c are having a moment in the compounding world right now, and providers are asking good questions about it. After two years stuck under restriction, these substances are finally moving. Here is what actually happened, what it changes for you today, and where Designer Drugs Labs stands as it plays out.

What Actually Changed

Back in late 2023, the FDA placed a batch of peptides into Category 2 of its interim 503A bulk drug substances list. Category 2 is the agency's flag for substances it has concerns about, and the practical effect was a wall in front of compounding them.

In April 2026, that wall came down for twelve of them. The nominations that had put these peptides on the list were withdrawn, and the FDA removed them from Category 2 later that month. BPC-157, TB-500, and MOTS-c were in the group. This did not happen on its own. It came after two years of steady pressure from pharmacies, prescribers, and patient advocates. [1]

What This Means in Practice

Here is the part worth being careful about, because it is where most of the confusion lives.

Coming off Category 2 is a win, but it is not a green light to compound. The FDA did not move these peptides to Category 1, the list of substances cleared for compounding, and none of them are approved drugs. They are currently in a gray zone, waiting while the agency decides what comes next. [2]

That sounds like a caveat, and it is, but it is also the good news. A gray zone with a scheduled review beats an indefinite ban. There is a process now, and a date on the calendar.

If you are fielding patient questions about these peptides today, check the current compounding status with your own pharmacy and compliance contacts first. The framework is still in motion, and it is moving faster than these things usually do.

What Happens Next

The date that matters is July 23 and 24, 2026. That is when the FDA's Pharmacy Compounding Advisory Committee meets to review several of these peptides for 503A eligibility, under docket FDA-2025-N-6895. The agenda: [3]

• July 23: BPC-157, KPV, TB-500, and MOTS-c

• July 24: Emideltide (also called DSIP), Semax, and Epitalon

While the committee advises the FDA, it does not approve anything itself, so its votes are recommendations. And it has set a high bar before. In its recent peptide reviews the committee recommended against the nominations it considered, so a clean sweep of approvals in July is not the likely outcome. What the meeting will do is put the safety and clinical data on the record and show how the agency is thinking. For a category this active, that visibility is worth a lot on its own.

There is also a way to be part of it. The FDA opened a public comment docket for the meeting. Providers with clinical experience or patient outcome data can submit written comments through regulations.gov. Get yours in by July 9 and it goes straight to the committee. The docket stays open through July 22. [4]

One more thing to keep straight; not every peptide is on the same clock. GHK-Cu, the copper peptide, is not on the July agenda and is expected to be evaluated later. We are tracking those separate timelines as the dates firm up.

Looking Ahead

The direction here is genuinely encouraging. As the review moves forward and more data comes in, the door for compounding pharmacies to responsibly offer peptide therapies could keep opening. This is the kind of progress that tends to stick, because it is being built on a real regulatory footing instead of a loophole.

Where Designer Drugs Labs Stands

We’re watching this closely, but not from the sidelines. We’re already in the formulation and evaluation phase so that we can move quickly if and when an appropriate regulatory pathway opens, in line with FDA guidance.

The work is not just formulation. We’re also running extensive potency-over-time testing on these formulations, measuring stability, potency, sterility, and quality across the shelf. The point is simple. When the pathway is there, we want peptide formulations that are already proven out and ready to go.

And, as always, we source only from reputable manufacturers and hold the line on quality at every step, because the ingredients, the testing, and the oversight are what patient outcomes actually ride on.

Set up a free provider account or schedule a call with our clinical team to discuss how this works in practice.

Sources

1. Federal Register, Pharmacy Compounding Advisory Committee; Notice of Meeting and Establishment of a Public Docket (Docket FDA-2025-N-6895), April 16, 2026. federalregister.gov

2. Frier Levitt, FDA to Remove 12 Peptides from the Category 2 "Do Not Compound" List and What It Means for Pharmacies, 2026. frierlevitt.com

3. U.S. Food and Drug Administration, July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov

4. Regulations.gov, Public Comment Docket FDA-2025-N-6895. regulations.gov